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~ Sul!tll!nlld Pt#Ie!M GP IIb/!lla IB!ockade With Onl! 
Ofbofllmn: !.~edm P h a ~ l ~  Ruu!ts of the 
SOAR StY ,  
J J, Ferguso~. PC, IDe~lwanm, 01  Kem~akeS, D Filzgerak:L R.J, A~r~,  
DM, Bums, B.S. ~ k L  ~ ~ ~ tnse~le, Houston. TX a,"~ G, 
~ '~k~ SOAR (Safe~/el (~tx~t~n in Acute Coronary Research) m 
a ran(~om!zeOL ~ study ~ to compare four ~ge 
~S oi the oral i~atelet GP !roA!la J~biter Orbofiban to p l~ in pahenls 
with ~ angina m recent (>6 hours b~ ~ l~ houm) myocardial infarc- 
tion. Patients (n = 259) were r a ~  to recewe Odbofiban (30, 40, 50 
mg BID or 50 mg QO) O, I~¢ebo re, up to 3 montt'~ All pa~ents recetved 
coz~-~tant as~nn (162 mo~6~y) 
~ "  E~ vtvo m~t~ el platetet ~ to agon~l (20. M ADP) 
wa~ meastm~l on [~/1  ax~l al 2 and 4 ~ (n = 145). 
Res~/~: The ~t t~n of plaletet aggregatm~ tO ADP at trough and peak 
following 2 weeks el dosteg were smear to IP, e 4 week results show~ befaw: 
- 
Conctus~n; Orbofiban produced a dose-related increase in ADP 20~,M 
platetet aggregabon inhibition. Target therapeutic ranges of ptatelet inh~b(t~on 
(60-80% arYJ 40-60% throughout he desmg interval) are achievable w~th 
BID dosing 
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-~  Clinical of Integrilin in Unstable Angina is Efficacy 
Accompanied by a Modest Increase in Hemorrhagic 
Risk: The PURSUIT Tdal 
AM. Lincoff. R.A. Hmnngton. R.M. Caltff. LG  Berdan. M.M. Kitt, 
8.D. Weathedy. N.S. Kleiman. E.J. Topoi. For the PURSUIT Investigators. 
Cleveland Clinic Foundation. Cleveland. OH and Duke Clinical Research 
Institute. Durham, NC, USA 
Background: Integrilin" (Eptifibatide). a cyclic KGD pept~de inhibitor of the 
ptatelet GP lib/Ilia receptor, was evaluated in the randomized, double-blind. 
placebo-contrelled PURSUIT trial among 10,948 pts with unstable angina, 
Eptifibatide treatment (180 pg/kg bolus, 2.0 pg/kg/min infusion) for up to 
72-96 hre was assOCiated with an absolute 1.5°,'o reduction in the incidence 
of death or MI within 30 days (15.7 vs 14.2%, p = 0.0424). 
Methods: Bleeding complications during the hospitalization penod were 
defined as severe (intracraniat or causing hemodynamic v'ompromise), rood- 
erate (requiring transfusion), or mild (all other). 
Resuffs/Conclusions: Moderate or severe bleeding (most often at s~tes 
of vascular access) was increased with eptifibatide, particularly in pts who 
did not require bypass surgery. Thus, reduction in ischemic events with 
PlaCebO Eptifibatide 
Moderate or Severe Breed 9.9";, 128%" 
Moderate or Severe Bleed w/o CABG 2.0% 52% 
RBC or Whole Blood Transfusion 9.3% 11.8% 
Transfusion w/o CASG 1.8% 44¢'" 
Intracranial Bteed 0.09% 0.11% 
"p. 00001 
eptifibatl~ i~ a.Chlevecl aLt ~ CO~t of a modest inc f (~ if~ C1 .'~K'.alty -~ ,l]~dlCaPff 
bleeding and transfusionS, but no inCre~se ~n intracrantal herrnO~t~ge 
9:30 
[8~ ThfombocytOp(mll Wlth GP .bs111g l.hlbltom: 
. . . . .  A l~avA.aly=l= 
R,P Gi~l!ano, R,R, Hy~tt, J~  8ng/~m ar~ ~nen~ ~ ~ ~rva~ 
Med~ca~ SoP, eel, Bo~ton, M4, USA 
~ m  (GP) Ilb/llla ~ ,  Sun-~a~ ~fa r~Oat'mg rates to 
and between agents fS sparse, 
Me~."  We pedot'me~ ,~ meta.analylsis Of all placebO-cOntrolted 
It-Ill clinK;a! teals of GP llb~ll!a~ mh~tom using the ~ n  ~ La~ 
ranOom effects ~1 ~ estimate the odds ratio of ~.Plt foe ~ V~ pl~-'ebo, 
S~gte~p analyses efrat*tied ~ drug ~nd requited use Ol hepam~ were amo 
pe~ormed, 
Re,J~/t~, Data on ~ Pit was avaitable for 25 0f the 26 teals ~ AIP 
solute rates 0f ;Pit ranged from 0~-1~.  depending on the clinical scena,o 
anO drag. The ovu,af! ~ rate of .~Plt for 13.093 I~1~'116 treated 
GP Iib/llla mh*bffo~ was 23% Odo's ratios with 95% CIs for risk ot ~Pff am 
shown below tar sefeete~ drugs, teals with vs, without fequIft~ hepann, and 
the overall mela.ana~m. 
C.onc/us~rm.' Use of GP Ill.Ilia inll~b~ors increases ~ne nsk Of ~PIt by 
apprcmimately 42% compared to ptacebo. Currenl sludies do not demonstrate 
s~gmficant differences between drugs, or in the pr~e or ~nce  ot 
hepann. Hepann, in comb4nation wffh a GP lib/Ilia rob, biter, lP¢~ases 
obsenmd absolute rate of ~.PIL but does not synergmtcally increase ~e ns~. 
gts" OR 95%Cf 
A~cr~xmab 6.342 t 76 (O 92, 3 37l 
"13r~'~an 7,158 I 63 (0 94. 2611 
Ep~fibat~e 4618 104 (060, t 80) 
Lam~bart 3.000 O 63 (020, 3 49) 
Prepann requ;red 12.761 1 38 10 88. 2. f 6) 
hepann not required 8.799 1 46 (092 2 32) 
Air treats 215.50 f42 ( f 07, ! B9f 
" rn~s  all placebo anO treate-.t ~S 
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B~- - - -~  Value of  in Predicting Therapeutic Troponins 
Efficacy of  Abc ix imab in Patients With Unstable 
Angina 
CW Harem, C Heeschen. 8.U. Getclmann, E 8amathan, M.L S,moons ~ 
For the CAPTURE InveStigators; Umversrty Hospdal Eppendort, Hamburg, 
Germany, ' Erasmus Unwermty Rotterdam. The Net,~erlancls 
Background: In patmnts (pts) wffh acute corenaw syndromes mc'roemboliza- 
t~on from ruptured atheroseterotic plaques may cause minor myocardial infury 
detectable by c=rcuta~ng troponms. This was shown to be assocmted with an 
adverse short and long term outcome. The CAPTURE teal demonslrated that 
platelet inhibition with abetximab reduces risk for myocardial infarction (AMI) 
at~J death in pts w,h refractory unstable angina p,or to and after PTCA. 
The pre~em study therefore invest~gated whether troponin T (cTnT) allows 
to predict this benefit, 
Methods and Resuffs: In 226 of 546 (41%) pts receiving aboximab and 
219 of 547 (40%) pts recewmg placebo cTnT L.0.t0 noJml) was found on 
study entq/. Event rates (death, AMI) dunng the 24 to 36 hours treatment 
phase before coronary interventions: 
cTnT nag CTnT pos p-value 
aboxrmaD 06% 0.9% ns 
Placebo O 9°¢' 4 1% p = 003 
p-v..~mue n:; p = 0 03 
Ounng the following PTCA abciximab reduced nsk in cTnT pos, as well 
as cTnT neg. pts (4.8% placebo vs. 19%. p = 0.04) 
Conctumons: cTnT identifies pts w~th unstable angina who benefit from 
abciximab through eliminating exCessive nsk prior to PTCA. Therefore. it 
may serve as a marker to initiate this treatment. All pts benefit equally from 
abeiximab during interventions, 
